Research programme: microRNA based therapeutics - miReculeAlternative Names: MIR 101; MIR-101 - miRecule
Latest Information Update: 04 Oct 2016
At a glance
- Originator miRecule
- Class MicroRNAs; Oligoribonucleotides; RNA binding proteins
- Mechanism of Action MicroRNA modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Head and neck cancer
Most Recent Events
- 28 Sep 2016 Preclinical trials in Head and neck cancer in USA (Parenteral) before September 2016 (miRecule pipeline, September 2016)
- 15 Mar 2016 Biomarkers information updated